

Journal of Visualized Experiments

SA- β -Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

--Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE58133R2
Full Title:	SA- β -Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
Keywords:	aging; Cell Senescence; cell death; β -Galactosidase; High Throughput Screening; Senolytics; Senomorphics; Senotherapeutics
Corresponding Author:	Heike Fuhrmann-Stroissnigg Scripps Florida Jupiter, UNITED STATES
Corresponding Author's Institution:	Scripps Florida
Corresponding Author E-Mail:	hefust@gmail.com
Order of Authors:	Heike Fuhrmann-Stroissnigg Diego Grassi Yuan Yuan Ling Laura J Niedernhofer Paul D Robbins Fernando E Santiago
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	University of Minnesota, Minneapolis, MN, USA

TITLE:

SA- β -Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

AUTHORS, AFFILIATIONS:

Heike Fuhrmann-Stroissnigg¹, Fernando E. Santiago^{1,2}, Diego Grassi¹, YuanYuan Ling¹, Laura J. Niedernhofer^{1,2}, Paul D. Robbins^{1,2}

¹Department of Molecular Medicine and the Center on Aging, The Scripps Research Institute, 130 Scripps Way, Jupiter, FL, USA

²Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA

²Institute on the Biology of Aging and Metabolism, University of Minnesota, Minneapolis, MN, USA

Corresponding Author:

Paul D. Robbins (probbins@umn.edu)

Email Addresses of Co-Authors:

Heike Fuhrmann-Stroissnigg (hefust@gmail.com)

Fernando E. Santiago (fsantiag@umn.edu)

Diego Grassi (diegograssi24@gmail.com)

YuanYuan Ling (yyling88@gmail.com)

Laura J. Niedernhofer (lniedern@scripps.edu)

KEYWORDS :

Aging, Cell Senescence, Cell Death, Senescence Associated β -Galactosidase, High Throughput Screening, Senolytics, Senomorphics, Senotherapeutics

SUMMARY:

Cellular senescence is the key factor in the development of chronic age-related pathologies. Identification of therapeutics that target senescent cells show promise for extending healthy aging. Here, we present a novel assay to screen for the identification of senotherapeutics based on measurement of senescence associated β -Galactosidase activity in single cells.

ABSTRACT:

Cell senescence is one of the hallmarks of aging known to negatively influence a healthy lifespan. Drugs able to kill senescent cells specifically in cell culture, termed senolytics, can reduce the senescent cell burden in vivo and extend healthspan. Multiple classes of senolytics have been identified to date including HSP90 inhibitors, Bcl-2 family inhibitors, piperlongumine, a FOXO4 inhibitory peptide and the combination of Dasatinib/Quercetin. Detection of SA- β -Gal at an increased lysosomal pH is one of the best characterized markers for the detection of senescent cells. Live cell measurements of senescence-associated β -galactosidase (SA- β -Gal) activity using the fluorescent substrate C₁₂FDG in combination with the determination of the total cell number using a DNA intercalating Hoechst dye opens the possibility to screen for senotherapeutic drugs

that either reduce overall SA- β -Gal activity by killing of senescent cells (senolytics) or by suppressing SA- β -Gal and other phenotypes of senescent cells (senomorphics). Use of a high content fluorescent image acquisition and analysis platform allows for the rapid, high throughput screening of drug libraries for effects on SA- β -Gal, cell morphology and cell number.

INTRODUCTION:

Cellular senescence was described for the first time by Leonard Hayflick and Paul Moorhead, who showed that normal cells had a limited ability to proliferate in culture¹. Senescent cells fail to proliferate despite the presence of nutrients, growth factors and lack of contact inhibition, but remain metabolically active². This phenomenon is known as replicative senescence and was mainly attributed to the telomere shortening, at least in human cells³. Further studies have shown that cells can also be induced to undergo senescence in response to other stimuli, such as oncogenic stress (oncogene induced senescence, OIS), DNA damage, cytotoxic drugs, or irradiation (stress induced senescence, SIS)⁴⁻⁶. In response to DNA damage, including telomere erosion, cells either senesce, start uncontrolled cell growth, or undergo apoptosis if the damage cannot be repaired. In this case, cell senescence seems to be beneficial as it acts in a tumor suppressive manner². In contrast, senescence is increased with aging due to the accumulation of cellular damage including DNA damage. Since senescent cells can secrete cytokines, metalloproteinases and growth factors, termed the senescence-associated secretory phenotype (SASP), this age-dependent increase in cellular senescence and SASP contributes to decreased tissue homeostasis and subsequently aging. Also, this age-dependent increase in the senescence burden is known to induce metabolic diseases, stress sensitivity, progeria syndromes, and impaired healing^{7,8} and is, in part, responsible for the numerous age-related diseases, such as atherosclerosis, osteoarthritis, muscular degeneration, ulcer formation, and Alzheimer's disease⁹⁻¹³. Eliminating senescent cells can help to prevent or delay tissue dysfunction and extend healthspan¹⁴. This has been shown in transgenic mouse models¹⁴⁻¹⁶ as well as by using senolytic drugs and drug combinations that were discovered through both drug screening efforts and bioinformatic analysis of pathways induced specifically in senescent cells¹⁷⁻²². Identifying more optimal senotherapeutic drugs, able to more effectively reduce the senescent cell burden, is an important next step in the development of therapeutic approaches for healthy aging.

Senescent cells show characteristic phenotypic and molecular features, both in culture and in vivo. These senescence markers could be either the cause or the result of senescence induction or a byproduct of molecular changes in these cells. However, no single marker is found specifically in senescent cells. Currently, senescence-associated β -galactosidase (SA- β -Gal) detection is one of the best-characterized and established single-cell based methods to measure senescence in vitro and in vivo. SA- β -Gal is a lysosomal hydrolase with an optimal enzymatic activity at pH 4. Measuring its activity at pH 6 is possible because senescent cells show increased lysosomal activity^{23,24}. For living cells, increased lysosomal pH is obtained by lysosomal alkalization with the vacuolar H⁺-ATPase inhibitor Bafilomycin A1 or the endosomal acidification inhibitor chloroquine^{25,26}. 5-Dodecanoylaminofluorescein Di- β -D-galactopyranoside (C₁₂FDG) is used as substrate in living cells as it retains the cleaved product in the cells due to its 12 carbon lipophilic moiety²⁵. Importantly, SA- β -Gal activity itself is not directly connected with any pathway identified in senescent cells and is not necessary to induce senescence. With this assay, senescent

cells can be identified even in the heterogeneous cell populations and aging tissues, such as skin biopsies from older individuals. It also has been used to show a correlation between cell senescence and aging²³ as it is a reliable marker for senescent cell detection in several organisms and conditions²⁷⁻³⁰. Here, a high throughput SA- β -Gal screening assay based on the fluorescent substrate C₁₂FDG using primary mouse embryonic fibroblasts (MEFs) with robustly oxidative stress induced cell senescence is described and its advantages and disadvantages are discussed. Although this assay can be performed with different cell types, the use of *Ercc1*-deficient, DNA repair impaired MEFs allows for more rapid induction of senescence under conditions of oxidative stress. In mice, reduced expression of the DNA repair endonuclease ERCC1-XPF causes impaired DNA repair, accelerated accumulation of endogenous DNA damage, elevated ROS, mitochondrial dysfunction, increased senescent cell burden, loss of stem cell function and premature aging, similar to natural aging^{31,32}. Similarly, *Ercc1*-deficient MEFs undergo senescence more rapidly in culture¹⁷. An important feature of the senescent MEF assay is that each well has a mixture of senescent and non-senescent cells, allowing for the clear demonstration of senescent cell-specific effects. However, although we believe that the use of oxidative stress in primary cells to induce senescence is more physiologic, this assay also can be used with cell lines where senescence is induced with DNA damaging agents like etoposide or irradiation.

PROTOCOL:

Animal use was approved by the Scripps Florida Institutional Animal Care and Use Committee.

1. Generation of senescent murine embryonic fibroblast (MEF) – 12-15 days

1.1. Isolate wild type and *Ercc1*^{-/-} MEFs from pregnant female mice at embryonic day 13 (E13) as described previously³³.

NOTE: All following steps are carried out in a tissue culture hood under aseptic conditions and using sterile instruments.

1.2. Resect the embryo head above the eyes.

1.3. Remove the red tissue (heart and liver) and use them for genotyping if necessary.

1.4. Prepare 500 mL of a 1:1 mixture of Dulbecco's Modified Eagle's Medium (DMEM) and Ham's F10 with 10% fetal bovine serum, 1x nonessential amino acids, penicillin, and streptomycin as growth medium and warm it up to 37 °C for around 15 min before each use. Store growth medium at 4 °C.

1.5. Incubate the rest of the embryo with 0.25% trypsin/EDTA for 10 min.

1.6. Mince the embryo into 1 mm pieces and pipette the tissue up and down several times.

1.7. Add 10 mL of growth medium and plate tissues of one embryo per 10 cm diameter cell culture plate (passage 0).

1.8. Cultivate cells at 37 °C, 3% O₂, 5% CO₂.

NOTE: Only MEF cells attach to non-coated tissue culture plates under these conditions.

1.9. Change medium every day in passage 0 to remove non-attached tissue and cell fragments.

NOTE: Depending on the size of the embryo and the quality of the isolation, cell usually reach confluency after 2 to 3 days.

1.10. Trypsinization

1.10.1. Carefully remove the growth medium and wash cells with 10 mL of 1x PBS two times.

1.10.2. Add 2 mL of a 0.025% trypsin/EDTA solution to cells in 10 cm diameter plates and incubate at 37 °C for 2-3 min.

1.10.3. Make sure that cells are detached from the surface by inspecting the cells under the microscope.

1.10.4. Terminate trypsin digestion by adding the same amount of growth medium.

1.10.5. Transfer the cells to a conical tube and centrifuge cells at 200 x *g* for 3 min and discard the supernatant.

1.10.6. Resuspend cells carefully in fresh growth medium, count cells and seed them in new plates at the projected cell density.

1.11. For non-senescent sub cultivation split confluent cells 1:4 and extend for another passage at 3% O₂, 37 °C to yield more cells (passage 1).

NOTE: At this point the cells can either be maintained in culture or stored for later use in liquid nitrogen, in cryovials containing approximately 1 million cells each. This step also offers the possibility to generate a mixed batch of cells from different animals to reduce variability coming from single animal analysis.

1.12. To induce cell senescence, seed split confluent cells from passage 1 at a ratio of 1:4 and incubate them at 20% O₂, 37 °C, 5% CO₂ for 3 days; these culture conditions are atmospheric for oxygen.

NOTE: Cultivation of cells and blastocysts under ambient oxygen concentrations can elevate markers of cellular senescence specifically when DNA damage repair is impaired³⁴⁻³⁶.

1.13. Repeat this procedure for 2 more passages.

1.14. To monitor cellular senescence, measure the gradual increase in cell diameter and cell volume during each trypsinization step using an advanced Coulter cell counter system.

1.15. Assess the reduction in cell proliferation by determination of population doubling (PD) using the equation

$$PDT = (t_2 - t_1) / 3.32 \times (\log n_2 - \log n_1)$$

NOTE: Population doubling time was only used for non-senescent cells.

1.16. Use early passage wild-type or *Ercc1*^{-/-} MEF cells that were kept at 3% O₂, 37 °C, 5% CO₂ as non-senescent control cells.

2. Senescent associated β-Gal screening assay – 2-3 days

2.1. Prepare 10 mM stock solutions in DMSO of all drugs to be tested and store aliquots at -80 °C. Do not freeze-thaw stock solutions as this may decrease the activity of drugs.

NOTE: Here, the HSP90 inhibitor 17DMAG was used as a senolytic drug capable of specifically killing senescent cells¹⁷.

2.2. On the day of the experiment thaw the aliquot, dilute the drugs in fresh culture medium and add to the cells containing conditioned medium at a 1:1 ratio to yield the final concentration in growth medium.

2.3. Use 96-well pre-dilution plates for serial dilutions and drug combinations.

NOTE: For MEF cells, it was empirically determined that DMSO concentrations should not exceed 2% and control cells treated with highest DMSO concentrations used should be included in each run.

2.4. Seed 5 x 10³ senescent cells or 3 x 10³ non-senescent cells per well in 96 well plates at least 6 h prior to treatment in 100 μL of growth medium and incubate at 20% O₂, 37 °C, 5% CO₂.

NOTE: Cells should be about 80% confluent before treatment.

2.5. Use black wall/clear bottom tissue culture, treated 96 well plates to minimize fluorescent signal crosstalk and background.

NOTE: However, clear plates have also been tested successfully.

2.6. Add drug dilutions to MEF cells and incubate for 24 h to 48 h under 20% O₂, 37 °C, 5% CO₂ conditions.

2.7. Keep non-senescent cells under 3% O₂, 37 °C, 5% CO₂ conditions.

2.8. For lysosomal alkalization, prepare a 10 mM bafilomycin A1 solution, aliquot and keep frozen at -20 °C.

2.9. For fluorescence analysis of SA-β-Gal activity, prepare a 2 mM C₁₂FDG stock solution, store at -20 °C, and protect from light.

2.10. For the working solution, prepare 100 μM C₁₂FDG in growth medium on the day of experiment.

NOTE: All (incubation) steps involving C₁₂FDG should be performed in the dark.

2.11. Remove the drug solution and wash cells 1 time with 100 μL of 1x PBS.

2.12. Induce lysosomal alkalization by pretreating cells with 90 μL of a 100 nM bafilomycin A1 solution prepared in fresh cell culture medium for 1 hour at 20% O₂, 37 °C, 5% CO₂.

2.13. Add 10 μL of 100 μM C₁₂FDG working solution to the culture medium (final concentration 10 μM).

2.14. Incubate cells for 2 h.

2.15. Add 2 μL of a 100 μg/mL Hoechst 33342 dye (final concentration 2 μg/mL) to the culture and incubate for 20 min.

2.16. Remove media and add 100 μL of fresh growth medium.

3. Quantitative high content fluorescent image analysis

3.1. Use a high content fluorescent image acquisition and analysis platform to acquire fluorescent images of the cells in the two channels appropriate for the capture of Hoechst and C₁₂FDG fluorescence (e.g., DAPI and FITC channel presets, respectively).

NOTE: Acquisition protocols require the definition of several variables that are specific to the assay. The purpose of an acquisition protocol is to capture an adequate number of in-focus fluorescent images of sufficient numbers of cells for downstream quantitative analysis.

3.2. Develop an appropriate analysis protocol by selecting each channel and defining, by adjusting one or more selective criteria, what qualifies as a feature of interest in each channel.

3.2.1. For the nucleus, use so segmentation pre-sets (e.g., nuclear segmentation, vesicle segmentation, cytoplasm segmentation) that will allow the identification of cellular organelles on the basis of multiple criteria including morphology, size, and signal intensity. Adjust these criteria to include nuclei while excluding nuclear fragments and debris which may have a signal, but which are, for example, too large or too small to be nuclei.

3.2.2. Check the signal in the FITC channel which is fluorescence from cleaved C₁₂FDG and represents the amount of senescence-associated β-galactosidase activity in the cells.

NOTE: Senescent cells have a higher senescence-associated β-galactosidase activity than non-senescent cells; however, C₁₂FDG fluorescence will be non-discrete and continuous, necessitating the establishment of a threshold between what is considered a C₁₂FDG-positive and a C₁₂FDG-negative cell.

3.2.3. Using commercially available analytical software, generate a count of instances in which a defined region surrounding the nucleus (a presumptive cell) has overlapped at least once with an above-threshold C₁₂FDG.

NOTE: The analytical software automatically generates a count using target linking. This is the assay's practical definition of a senescent, C₁₂FDG-positive cell.

3.3. Analyze all samples in triplicate with 3-5 fields per well and mean values and standard deviations being calculated accordingly.

3.4. Calculate the percentage of senescent cells using the following formula:

$$\text{Senescent cells (\%)} = \frac{\sum (\text{Senescent cells})}{\sum (\text{Total cells})} \times 100$$

4. Assay validation parameters

4.1. For all samples intra- and inter-assay coefficient of variations (%CVs) were calculated using the following formula:

$$\text{Intra-assay CV (n = 10 repeats measured in one experiment)} = \frac{\text{average}}{n} \times 100 (\%)$$

$$\text{Inter-assay CV (n = 5 independent experiments)} = \frac{\text{standard deviation}}{\text{average}} \times 100 (\%)$$

4.2. For screening purposes, determine the Z' value, a statistical parameter to evaluate the quality of an assay, from cells treated with 200 nM rapamycin for 24 h at 20% O₂, 37 °C, 5% CO₂ (a positive control for senotherapeutic drugs) and untreated senescent cells (negative control).

NOTE: The Z' value was calculated according to Zhang et al.³⁷. Z' values between 0.5 and 1 indicate that an assay can be used for drug screening.

REPRESENTATIVE RESULTS:

SA- β -Gal activity can be detected in cells that are induced to senesce by various ways from replicative exhaustion, genotoxic and oxidative stress, to oncogene activation^{23,25,38}. In the current model using *Ercc1*-deficient mouse embryonic fibroblast cells, normoxic growth conditions (20% O₂) were sufficient to induce cell senescence after cultivating them for a few passages. Wild type MEFs also undergo senescence but require additional passages at 20% O₂. **Figure 1** shows the workflow of the screening assay starting with the isolation of primary MEF cells from *Ercc1*-deficient mouse embryos, to the induction of cell senescence by oxidative stress, and finally to the analysis of microscopic data obtained with a high content fluorescent microscope. **Figure 2** shows representative images of MEF cell cultures containing non-senescent (young) cells (**Figure 2**, left), about 50% senescent cells in passage 5 (**Figure 2**, center), and senescent cells treated with a senolytic drug (**Figure 2**, right). **Figure 3A** shows representative images for automatic, software generated quantitative analyses of senescent cells. **Figure 3B** demonstrates the elimination of background β -galactosidase activity by bafilomycin-A. **Figure 4** shows possible outcomes of senescent cell cultures treated with drugs including senescent cell killing (senolytic) and senescence modulating (senomorphic) drugs as described in Fuhrmann-Stroissnigg et al.¹⁷.

FIGURE AND TABLE LEGENDS:

Figure 1. Schematic overview of screening assay and timeline. MEF cells are isolated from pregnant mice and put on cell culture treated plastic plates for a few days to expand. Early passage cells can be frozen in liquid nitrogen and can be used for screening at a later time point. Cell senescence is induced by oxidative stress by passage at 20% O₂ and cells are exposed to drugs once they have reached a robust senescent state. Data analysis including the amount total and remaining senescent cells is performed. The timeline, in days, indicates the duration of one experiment.

Figure 2. Representative Images of non-senescent, senescent and senescent cells treated with 100 nM of the senolytic drug 17DMAG. Blue fluorescence indicates DNA staining with Hoechst 33324 whereas green fluorescence indicates SA- β -Gal staining with C₁₂FDG. Bright green staining represents SA- β -Gal positive senescent cells whereas dim staining represents SA- β -Gal low or negative, non-senescent cells. Please note that senescent cells usually have bigger cell size and are flattened.

Figure 3. Representative Images of a senescent MEF cell culture analyzed with commercial software. (A) SA- β -Gal positive cells (SA- β -Gal⁺) cells are outlined in green (green arrows), SA- β -Gal negative (SA- β -Gal⁻) are outlined in red (red arrows). Left and right panels show nuclear (Hoechst) and C₁₂FDG (FITC) signal, respectively. Only areas that stain positive for Hoechst (contain a nuclei) are considered as cells. (B) A comparison of Bafilomycin-A treated and untreated cells. Residual β -galactosidase activity present in all cells is reduced by lysosomal acidification

Figure 4. Scheme of possible outcomes of drug treatment. Drugs can have different effects on senescent and non-senescent cells including kill senescent cells (senolytics) or suppress the SA- β -Gal senescent phenotype (senomorphics). Together these two classes are termed senotherapeutics. This figure has been modified from Fuhrmann-Stroissnigg et al.¹⁷.

DISCUSSION:

SA- β -Gal is a well-defined biomarker for cellular senescence originally discovered by Dimri et al. (1995) showing that senescent human fibroblasts have increased activity of SA- β -Gal when assayed at pH 6²³ compared to proliferating cells. Meanwhile, in vitro and in vivo assay for SA- β -Gal have been established for different cell types and tissues^{25,39,40}. The fluorescence based single-cell method to measure SA- β -Gal in live cells described in this protocol is an excellent primary screening tool for drugs influencing cell senescence¹⁷. However, although SA- β -Gal is considered as one of the most convenient markers for senescent cell detection, additional markers for cellular senescence like the detection of cell cycle regulators p16^{Ink4A} and p21⁴¹, senescence associated secretory phenotype (SASP) proteins like IL-6, TNF α , HMGB1 and NF- κ B⁴², DNA damage repair markers like γ H2Ax and telomere associated DNA damage foci (TAFs)^{43,44}, senescence associated heterochromatin foci (SAHF)⁴⁵ or basic morphological markers like cell size and granularity need to be in place as confirmatory assays to ensure the senotherapeutic potential of drugs⁴⁰. Since the transition from a normal cell into a senescent cell is a slow process, the critical step in this method is to find the threshold that distinguishes between C₁₂FDG positive (senescent) and negative (normal) cells. This has to be determined empirically for each cell type and C₁₂FDG positive and negative controls have to be included in each experiment.

In addition to oxidative-stressed *Ercc1*^{-/-} MEFs, this method can be modified for other adherent cell types. Oxidative-stressed *Ercc1*-deficient mesenchymal stem cells (MSCs) and etoposide-treated human IMR90 cells were already successfully tested in the assay and can be used to screen for drugs¹⁷. However, times to induce senescence as well as drug treatment times and concentrations might vary.

The major limitation of this technique is that SA- β -Gal activity has shown to increase under certain senescent-independent conditions such cell contact inhibition or high cellular confluence^{46,47}. Areas containing “cell heaps” and cell cultures with over confluent cells can easily be determined and should be excluded from the analyses. In addition, background staining from green auto fluorescent lipofuscin vesicles increased in senescent cells can occur. In senescent MEF cells cultures they are negligible due to the brightness of C₁₂FDG but should be examined for each cell type⁴⁶. Hoechst staining of DNA usually does not lead to background staining. Some phenol ring containing drugs, however, might be fluorescent in UV light. Increase of the exclusion size of the UV positive fluorescence signal up to the size of actual cell nuclei might help to prevent unwanted detection of these drugs.

The most significant feature of the described assay is the fact that senescent as well as non-senescent cells are found in the same environment, allowing for assessment of drug effects on senescent and non-senescent cells simultaneously. The detection of the total cell number by counting cell nuclei gives a first indication about the cell killing potential of a drug. A decline in

cell numbers and cell senescence usually hints to senolytic drugs whereas a constant cell number with a reduced number of senescent cells usually indicates senomorphic drugs. Due to the short drug incubation time, effects like simultaneous proliferation of non-senescent cells and cell death of senescent cells leading to constant cell number (e.g., senolytic effect with senomorphic result) cannot be ruled out but are considered highly unlikely.

Future applications of this technique include the possibility to integrate additional live cell markers (e.g., apoptosis marker like AnnexinV and 7AAD⁴⁰) or markers for different intracellular compartments like mitochondria or lysosomes into the assay system. Concomitant monitoring of SA- β -Gal and other cellular markers during drug treatment can help to elucidate underlying cellular mechanism.

ACKNOWLEDGMENTS:

This work was supported by NIH Grants AG043376 (Project 2 and Core A, PDR; Project 1 and Core B, LJN) and AG056278 (Project 3 and Core A, PDR; and Project 2, LJN) and a grant from the Glenn Foundation (LJN).

DISCLOSURES:

The authors have nothing to disclose.

REFERENCES:

- 1 Hayflick, L., Moorhead, P. S. The serial cultivation of human diploid cell strains. *Experimental Cell Research*. **25** 585-621 (1961).
- 2 Campisi, J., di Fagagna, F. D. Cellular senescence: when bad things happen to good cells. *Nature Reviews Molecular Cell Biology*. **8** (9), 729-740 (2007).
- 3 Harley, C. B., Futcher, A. B., Greider, C. W. Telomeres shorten during ageing of human fibroblasts. *Nature*. **345** (6274), 458-460 (1990).
- 4 Zhu, J., Woods, D., McMahon, M., Bishop, J. M. Senescence of human fibroblasts induced by oncogenic Raf. *Genes and Development*. **12** (19), 2997-3007 (1998).
- 5 Dimri, G. P., Itahana, K., Acosta, M., Campisi, J. Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14(ARF) tumor suppressor. *Molecular and Cellular Biology*. **20** (1), 273-285 (2000).
- 6 Michaloglou, C. et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. *Nature*. **436** (7051), 720-724 (2005).
- 7 Niedernhofer, L. J. Tissue-specific accelerated aging in nucleotide excision repair deficiency. *Mechanisms of Ageing and Development*. **129** (78), 408-415 (2008).
- 8 Gitenay, D. et al. Glucose metabolism and hexosamine pathway regulate oncogene-induced senescence. *Cell Death & Disease*. **5** e1089 (2014).
- 9 Erusalimsky, J. D., Kurz, D. J. Cellular senescence in vivo: its relevance in ageing and cardiovascular disease. *Experimental Gerontology*. **40** (8-9), 634-642 (2005).
- 10 Kassem, M., Marie, P. J. Senescence-associated intrinsic mechanisms of osteoblast dysfunctions. *Aging Cell*. **10** (2), 191-197 (2011).
- 11 Campisi, J., Andersen, J. K., Kapahi, P., Melov, S. Cellular senescence: A link between cancer and age-related degenerative disease? *Seminars in Cancer Biology*. **21** (6), 354-359

439 (2011).

440 12 Golde, T. E., Miller, V. M. Proteinopathy-induced neuronal senescence: a hypothesis for
441 brain failure in Alzheimer's and other neurodegenerative diseases. *Alzheimers Research*
442 *& Therapy*. **1** (2), 5 (2009).

443 13 Telgenhoff, D., Shroot, B. Cellular senescence mechanisms in chronic wound healing. *Cell*
444 *Death & Differentiation*. **12** (7), 695-698 (2005).

445 14 Baker, D. J. et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated
446 disorders. *Nature*. **479** (7372), 232-236 (2011).

447 15 Baker, D. J. et al. Naturally occurring p16-positive cells shorten healthy lifespan. *Nature*.
448 10.1038/nature16932 (2016).

449 16 Childs, B. G. et al. Senescent intimal foam cells are deleterious at all stages of
450 atherosclerosis. *Science*. **354** (6311), 472-477 (2016).

451 17 Fuhrmann-Stroissnigg, H. et al. Identification of HSP90 inhibitors as a novel class of
452 senolytics. *Nature Communications*. **8** (1), 422 (2017).

453 18 Zhu, Y. et al. New agents that target senescent cells: the flavone, fisetin, and the BCL-XL
454 inhibitors, A1331852 and A1155463. *Aging (Albany NY)*. **9** (3), 955-963 (2017).

455 19 Zhu, Y. et al. Identification of a Novel Senolytic Agent, Navitoclax, Targeting the Bcl-2
456 Family of Anti-Apoptotic Factors. *Aging Cell*. 10.1111/ace1.12445 (2015).

457 20 Zhu, Y. et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs.
458 *Aging Cell*. 10.1111/ace1.12344 (2015).

459 21 Baar, M. P. et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in
460 Response to Chemotoxicity and Aging. *Cell*. **169** (1), 132-147 e116 (2017).

461 22 Jeon, O. H. et al. Local clearance of senescent cells attenuates the development of post-
462 traumatic osteoarthritis and creates a pro-regenerative environment. *Nature Medicine*.
463 10.1038/nm.4324 (2017).

464 23 Dimri, G. P. et al. A biomarker that identifies senescent human cells in culture and in aging
465 skin in vivo. *Proceedings of the National Academy of Sciences USA*. **92** (20), 9363-9367
466 (1995).

467 24 Itahana, K., Campisi, J., Dimri, G. P. Methods to detect biomarkers of cellular senescence:
468 the senescence-associated beta-galactosidase assay. *Methods in Molecular Biology*. **371**
469 21-31 (2007).

470 25 Debacq-Chainiaux, F., Erusalimsky, J. D., Campisi, J., Toussaint, O. Protocols to detect
471 senescence-associated beta-galactosidase (SA-[beta]gal) activity, a biomarker of
472 senescent cells in culture and in vivo. *Nature Protocols*. **4** (12), 1798-1806 (2009).

473 26 Cahu, J., Sola, B. A sensitive method to quantify senescent cancer cells. *Journal of*
474 *Visualized Experiments*. 10.3791/50494 (78) (2013).

475 27 Collado, M. et al. Tumour biology: Senescence in premalignant tumours. *Nature*. **436**
476 (7051), 642-642 (2005).

477 28 Krishnamurthy, J. et al. Ink4a/Arf expression is a biomarker of aging. *The Journal of Clinical*
478 *Investigation*. **114** (9), 1299-1307 (2004).

479 29 Mishima, K. et al. Senescence-associated beta-galactosidase histochemistry for the
480 primate eye. *Investigative Ophthalmology, Visual Science*. **40** (7), 1590-1593 (1999).

481 30 Melk, A. et al. Expression of p16INK4a and other cell cycle regulator and senescence
482 associated genes in aging human kidney. *Kidney International*. **65** (2), 510-520 (2004).

483 31 Niedernhofer, L. J. et al. A new progeroid syndrome reveals that genotoxic stress
484 suppresses the somatotroph axis. *Nature*. **444** (7122), 1038-1043 (2006).

485 32 Wang, J., Clauson, C. L., Robbins, P. D., Niedernhofer, L. J., Wang, Y. The oxidative DNA
486 lesions 8,5'-cyclopurines accumulate with aging in a tissue-specific manner. *Aging Cell*. **11**
487 (4), 714-716 (2012).

488 33 Jozefczuk, J., Drews, K., Adjaye, J. Preparation of mouse embryonic fibroblast cells suitable
489 for culturing human embryonic and induced pluripotent stem cells. *Journal of Visualized*
490 *Experiments*. 10.3791/3854 (64) (2012).

491 34 Jagannathan, L., Cuddapah, S., Costa, M. Oxidative stress under ambient and physiological
492 oxygen tension in tissue culture. *Current Pharmacology Reports*. **2** (2), 64-72 (2016).

493 35 Meuter, A. et al. Markers of cellular senescence are elevated in murine blastocysts
494 cultured in vitro: molecular consequences of culture in atmospheric oxygen. *J Assist*
495 *Reprod Genet*. **31** (10), 1259-1267 (2014).

496 36 Robinson, A. R. et al. Spontaneous DNA damage to the nuclear genome promotes
497 senescence, redox imbalance and aging. *Redox Biology*. **17** 259-273 (2018).

498 37 Zhang, J. H., Chung, T. D., Oldenburg, K. R. A Simple Statistical Parameter for Use in
499 Evaluation and Validation of High Throughput Screening Assays. *Journal Of Biomolecular*
500 *Screening*. **4** (2), 67-73 (1999).

501 38 Zhao, H., Darzynkiewicz, Z. Biomarkers of cell senescence assessed by imaging cytometry.
502 *Methods in Molecular Biology*. **965** 83-92 (2013).

503 39 Yang, N.-C., Hu, M.-L. A fluorimetric method using fluorescein di- β -D-galactopyranoside
504 for quantifying the senescence-associated β -galactosidase activity in human foreskin
505 fibroblast Hs68 cells. *Analytical Biochemistry*. **325** (2), 337-343 (2004).

506 40 Zhao, J. et al. Quantitative Analysis of Cellular Senescence in Culture and In Vivo. *Current*
507 *Protocols in Cytometry*. **79** 9 51 51-59 51 25 (2017).

508 41 Capparelli, C. et al. CDK inhibitors (p16/p19/p21) induce senescence and autophagy in
509 cancer-associated fibroblasts, "fueling" tumor growth via paracrine interactions, without
510 an increase in neo-angiogenesis. *Cell Cycle*. **11** (19), 3599-3610 (2012).

511 42 Coppe, J. P., Desprez, P. Y., Krtolica, A., Campisi, J. The senescence-associated secretory
512 phenotype: the dark side of tumor suppression. *Annual Review of Pathology*. **5** 99-118
513 (2010).

514 43 Mah, L. J., El-Osta, A., Karagiannis, T. C. GammaH2AX as a molecular marker of aging and
515 disease. *Epigenetics*. **5** (2), 129-136 (2010).

516 44 Hewitt, G. et al. Telomeres are favoured targets of a persistent DNA damage response in
517 ageing and stress-induced senescence. *Nature Communications*. **3** 708 (2012).

518 45 Narita, M. et al. Rb-mediated heterochromatin formation and silencing of E2F target
519 genes during cellular senescence. *Cell*. **113** (6), 703-716 (2003).

520 46 Georgakopoulou, E. A. et al. Specific lipofuscin staining as a novel biomarker to detect
521 replicative and stress-induced senescence. A method applicable in cryo-preserved and
522 archival tissues. *Aging-Us*. **5** (1), 37-50 (2013).

523 47 Severino, J., Allen, R. G., Balin, S., Balin, A., Cristofalo, V. J. Is β -Galactosidase Staining a
524 Marker of Senescence in Vitro and in Vivo? *Experimental Cell Research*. **257** (1), 162-171
525 (2000).

526





Figure 2

[Click here to access/download;Figure;JoVE58133 - revised Figure 2 - Fuhrmann-Stroissnigg.pdf](#)








Figure 4



Name of Material/ Equipment	Company
DMEM	Corning
Ham's F10	Gibco
fetal bovine serum	Tissue Culture Biologics
1x non-essential amino acids	Corning
bafilomycin A1	Sigma
C12FDG	Setareh Biotech
Hoechst 33342	Life Technologies
17DMAG	Selleck Chemical LLC
InCell6000 Cell Imaging System	GE Healthcare

Catalog Number	Comments/Description
10-013-CV	medium
12390-035	medium
101	serum
25-025-Cl	amino-acids
B1793	lysosomal inhibitor
7188	β -Gal substrate
H1399	DNA intercalation agent
50843	HSP90 inhibitor High Content Imaging System



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

SA- β -Galactosidase-Based Drug Screening Assay for

Author(s):

Fuhrmann-Stoissnig, Grassi, Ling, Niedernhofer and Robbins

Item 1 (check one box): The Author elects to have the Materials be made available (as described at

<http://www.jove.com/author>) via: ☒ Standard Access ☐ Open Access

Item 2 (check one box):



The Author is NOT a United States government employee.



The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.



The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JoVE"** means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JoVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. Retention of Rights in Article. Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. Grant of Rights in Video – Standard Access. This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. Grant of Rights in Video – Open Access. This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. Government Employees. If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such

statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. Likeness, Privacy, Personality. The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. Author Warranties. The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. JoVE Discretion. If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have

ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's

expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to me one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.


CORRESPONDING AUTHOR:

Name: Paul D. Robbins

Department: Molecular Medicine

Institution: The Scripps Research Institute

Article Title: SA-B-Galactosidase-based drug screening assay for the detection..

Signature:  Date: 3-7-18

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pdf on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email submissions@jove.com or call +1.617.945.9051

UNIVERSITY OF MINNESOTA

***Twin Cities Campus
Medical School and
College of Biological Sciences***

*Paul D. Robbins, Ph.D.
Associate Director, Institute on the Biology of Aging and Metabolism
Professor, Department of Biochemistry, Molecular Biology and Biophysics
4-112 Nils Hasselmo Hall, 312 Church St. SE
Minneapolis, MN 55455
Phone: 612-626-2291
Fax: 612-625-2163
Email: probbins@umn.edu*

October 30th, 2018


Vineeta Bajaj, Ph.D.
Review Editor
JoVE

Re: Ms. No. JoVE58133

Dear Dr. Bajaj:

Please find attached the revised manuscript (JoVE58133) from Fuhrmann-Stroissnigg *et al* entitled "SA- β -Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs" which we are re-submitting for publication in *JoVE*. As outlined below, we have addressed the excellent comments from the editors and believe the manuscript is now suitable for publication. We look forward to hearing from you regarding the status of the manuscript.

Sincerely,



Paul D. Robbins, Ph.D.

Responses to editorial comments:

Changes to be made by the Author(s):

- 1. The manuscript is formatted to match the journal's style. Please retain the same.**

As requested, the format was retained.

- 2. Please address all specific comments marked in the manuscript as well.**

All specific comments marked in the manuscript were addressed.

- 3. Please ensure that there are representative results present for all sections of the protocol.**

A representative bafilomycin result was added as Figure 3B.

- 4. Please provide results for the bafilomycin part.**

A representative bafilomycin result was added as Figure 3B.

- 5. Please refer all figures in the order.**

All figures are referred to in order.

- 6. Please upload the explicit copyright permission to reuse any figures from a previous publication. Explicit permission can be expressed in the form of a letter from the editor or a link to the editorial policy that allows re-prints. Please upload this information as a .doc or .docx file to your Editorial Manager account.**

Permission for use of figure 4 from Nature Communications is still pending. We will upload the permission statement as soon as we receive it.



Vineeta Bajaj <vineeta.bajaj@jove.com>

RE: Response Requested: JoVE Submission JoVE58133R2 - [EMID:8b671099f5decf23]

1 message

Heike Fuhrmann <hefust@gmail.com>
To: Vineeta Bajaj <vineeta.bajaj@jove.com>
Cc: Paul Robbins <probbins@umn.edu>

Tue, Nov 6, 2018 at 4:59 PM

Dear Vineeta,

Please find attached the response for the copyright permission. Please let me know if you need an additional statement or if I should add a screen shot of the open access statement to the protocol submission.

Best regards,

Heike Fuhrmann-Stroissnigg

Dear Heike Fuhrmann,

Thank you for contacting Copyright Clearance Center's Rightslink service.

I checked and was able to confirm that this article is included into a CC-BY license. Here is the statement available in the article page online:

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

Source: <https://www.nature.com/articles/s41467-017-00314-z#rightslink>

If your request falls under the above stated coverage. Then you may proceed with using the article. You may keep a screenshot copy of the page as a reference. However, if you require a formal letter, then it is best that you contact the publisher directly instead.

If you have any further questions please don't hesitate to contact a Customer Account Specialist at 855-239-3415 Monday-Friday, 24 hours/day.

Regards,
Nadine Sobusa
Customer Account Specialist
Copyright Clearance Center
[222 Rosewood Drive](#)
[Danvers, MA 01923](#)
www.copyright.com
+1.855.239.3415
[Facebook](#) - [Twitter](#) - [LinkedIn](#)

From: em.jove.145d9.5f0e47.2cf1098e@editorialmanager.com [mailto:em.jove.145d9.5f0e47.2cf1098e@editorialmanager.com] **On Behalf Of** Vineeta Bajaj

Sent: Monday, November 05, 2018 8:45 AM

To: Heike Fuhrmann-Stroissnigg

Subject: Response Requested: JoVE Submission JoVE58133R2 - [EMID:8b671099f5decf23]

CC: "Diego Grassi" dgrassi@scripps.edu, "Yuan Yuan Ling" yyling88@gmail.com, "Laura J Niedernhofer" lniedern@scripps.edu, "Paul D Robbins" probbins@scripps.edu, "Fernando E Santiago" fsantiago@umn.edu

Dear Dr Fuhrmann-Stroissnigg,

Regarding your JoVE submission JoVE58133R2 SA- β -Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs,

Please email the copyright permission as soon as possible. We cannot proceed further without this.

Please feel free to email me with any questions or concerns about your manuscript.

Best Regards,

Vineeta Bajaj, Ph.D.

Review Editor

JoVE

617.674.1888

Follow us: [Facebook](#) | [Twitter](#) | [LinkedIn](#)

[About JoVE](#)

In compliance with data protection regulations, please contact the publication office if you would like to have your personal information removed from the database.